William K. Oh, MD, presented “mCRPC: Lu-177 PSMA and Beyond” during the 27th Annual Southwest Prostate Cancer Symposium conference on October 17, 2024, in Scottsdale, Arizona.
How to cite: Oh, William K. “mCRPC: Lu-177 PSMA and Beyond.” October 17, 2024. Accessed Mar 2026. https://grandroundsinurology.com/mcrpc-lu-177-psma-and-beyond/
mCRPC: Lu-177 PSMA and Beyond – Summary
In this 24-minute presentation, William K. Oh, MD, a seasoned medical oncologist with over two decades of experience managing prostate cancer, discusses recent advancements in prostate cancer diagnosis and treatment, focusing on the transformative potential of PSMA diagnostics and LU-177 PSMA therapy.
Dr. Oh gives an overview of how PSMA diagnostics have revolutionized the identification of localized and metastatic prostate cancers, significantly altering clinical practice. He emphasizes the role of LU-177 in extending survival and improving the quality of life for patients with advanced prostate cancer, particularly those with metastatic castration-resistant prostate cancer (mCRPC).
Data from key clinical trials, including the VISION, TheraP, and SPLASH studies, are presented to highlight the efficacy of LU-177 in various stages of the disease. They demonstrate notable benefits in progression-free and overall survival rates compared to conventional therapies and underscore its potential in earlier treatment stages.
Dr. Oh reflects on the broader implications of PSMA-targeted treatments and theranostics for prostate cancer and potentially other cancers. This talk provides a comprehensive update on PSMA-based advancements and underscores the ongoing evolution of therapeutic strategies to enhance patient outcomes in prostate cancer care.
About the 27th Annual Southwest Prostate Cancer Symposium:
Presented by Program Chairs Nelson N. Stone, MD, Richard G. Stock, MD, and William K. Oh, MD, this conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
William K. Oh, MD, is the Director of Precision Medicine at the Yale Cancer Center, and aProfessor of Medicine for the Division of Medical Oncology at Yale School of Medicine in New Haven, Connecticut. Dr. Oh also serves as Medical Director for the Service Line at Smilow Cancer Hospital within the Greenwich Hospital.Dr. Oh’s specialties include the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers.Dr. Oh’s research interests include novel biomarkers and therapeutics in advanced prostate cancer.
Dr. Oh received his medical degree from New York University School of Medicine in New York, New York. He completed his internship and residency in Internal Medicine at Brigham and Women’s Hospital in Boston, Massachusetts. He then completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. Prior to joining Mount Sinai in 2009, Dr. Oh served as Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. He was also the founding Chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center.
In addition to serving as the Principal Investigator of multiple clinical trials in prostate cancer, Dr. Oh has developed large clinical databases and specimen repositories for genitourinary cancers at Harvard Medical School and the Dana-Farber Cancer Institute and at Mount Sinai, which have enrolled more than 10,000 patients with prostate, renal, and bladder cancers.Dr. Oh has authored more than 350 articles, reviews, and book chapters on topics relating to prostate, renal, bladder, and testicular cancers. He has edited three books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association, including the Guidelines Committee for Advanced Prostate Cancer. In addition to reviewing for top journals such as The New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr. Oh co-edits “Testicular Cancer” for Up to Date and is Associate Editor of CA: A Cancer Journal for Clinicians. He is a member of the prestigious American Society for Clinical Investigation and has been repeatedly selected as a Top Doctor in New York magazine, Castle Connolly, Best Doctors, and Super Doctors over the past decade.
